Tildacerfont
As of the edition of 20 October 2026, Tildacerfont is a small molecule: stopped in 2025; acts on CRHR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 6, 4 stopped early
- Disease areas
- Hormones; Pregnancy and women's health; Urinary and reproductive; Inherited and neonatal; Nutrition and metabolism; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Tildacerfont.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CRHR1 | Corticotropin-releasing hormone receptor 1 | P34998 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 2 | 0 | 4 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Spruce Biosciences | Lead sponsor of trials | 2017 to now |